WW de Herder - Concepedia

Author

WW de Herder

Erasmus MC

Also Known As

Herder W., De, W de Herder, W. De Herder, W. de Herder, WW de Herder

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Erasmus MC University of Turin Radboud University Medical Center Radboud University Nijmegen Charité - Universitätsmedizin Berlin

About

WW de Herder is an author at Erasmus MC specializing in medicine, pharmacology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	296
2	Pathology	2	2	64
3	Health Sciences	1	1	10
4	Endocrinology	1	1	232
5	Molecular Medicine	1	1	54

WW de Herder

Publications

409

Citations

H-Index

Page 1

	Year	Citations
Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly J Feenstra, WW de Herder, SMTH ten Have, The Lancet Active AcromegalyMedicineSomatostatin AnaloguesWeekly PegvisomantEndocrinology	2005	232
Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study Larry K. Kvols, Bertram Wiedenmann, Kjell Öberg, Journal of Clinical Oncology PathologyPhase Ii StudyPasireotide 300Tumor BiologyEndocrine Oncology	2006	54
DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients Yvonne M.H. Versleijen‐Jonkers, Sandra M.H. Claessen, Aurel Perren, Endocrine Related Cancer	2007	46
Sequential ACTH and catecholamine secretion in a phaeochromocytoma PS van Dam, A van Gils, MR Canninga‐van Dijk, European Journal of Endocrinology	2002	20
Central ghrelin production does not substantially contribute to systemic ghrelin concentrations: a study in two subjects with active acromegaly FM van der Toorn, J. A. M. J. L. Janssen, WW de Herder, European Journal of Endocrinology	2002	17
Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR Larry K. Kvols, Kjell Öberg, WW de Herder, Journal of Clinical Oncology	2005	15
Rare NOX3 Variants Confer Susceptibility to Agranulocytosis During Thyrostatic Treatment of Graves' Disease Peer Arts, GH Knarren, AH Mulder, Clinical Pharmacology & Therapeutics	2017	15
The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR Larry K. Kvols, J. E. Glusman, Elizabeth A. Hahn, Journal of Clinical Oncology Chemoprevention StrategyHealth-related QualityGastrointestinal PharmacologyChronic Illness Therapy-diarrheaCancer Management	2007	10

Page 1